Trade Quince Therapeuticks Inc - QNCX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0336 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001207% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.9739 |
| Open | 0.9848 |
| 1-Year Change | -4.1% |
| Day's Range | 0.9549 - 1.0382 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 0.9739 | -0.0203 | -2.04% | 0.9942 | 1.0382 | 0.9618 |
| Apr 16, 2025 | 0.9982 | 0.0000 | 0.00% | 0.9982 | 1.0082 | 0.9982 |
| Apr 15, 2025 | 0.9979 | -0.0003 | -0.03% | 0.9982 | 1.0182 | 0.9843 |
| Apr 14, 2025 | 0.9982 | 0.0000 | 0.00% | 0.9982 | 1.0082 | 0.9982 |
| Apr 11, 2025 | 0.9743 | 0.0277 | 2.93% | 0.9466 | 0.9980 | 0.9207 |
| Apr 10, 2025 | 0.9882 | -0.0062 | -0.62% | 0.9944 | 1.0082 | 0.9644 |
| Apr 9, 2025 | 0.9982 | -0.0300 | -2.92% | 1.0282 | 1.0682 | 0.9979 |
| Apr 8, 2025 | 1.1282 | -0.0600 | -5.05% | 1.1882 | 1.2082 | 1.1282 |
| Apr 7, 2025 | 1.1582 | -0.0200 | -1.70% | 1.1782 | 1.1882 | 1.1582 |
| Apr 4, 2025 | 1.2382 | 0.0500 | 4.21% | 1.1882 | 1.2382 | 1.1882 |
| Apr 3, 2025 | 1.2082 | -0.0600 | -4.73% | 1.2682 | 1.2682 | 1.2082 |
| Apr 2, 2025 | 1.2782 | 0.0100 | 0.79% | 1.2682 | 1.2782 | 1.2682 |
| Apr 1, 2025 | 1.2482 | -0.0200 | -1.58% | 1.2682 | 1.2782 | 1.2382 |
| Mar 31, 2025 | 1.2782 | 0.0000 | 0.00% | 1.2782 | 1.3082 | 1.2582 |
| Mar 28, 2025 | 1.3082 | -0.0200 | -1.51% | 1.3282 | 1.3482 | 1.3082 |
| Mar 27, 2025 | 1.3882 | 0.0200 | 1.46% | 1.3682 | 1.3882 | 1.2982 |
| Mar 26, 2025 | 1.3482 | 0.0100 | 0.75% | 1.3382 | 1.3482 | 1.3082 |
| Mar 25, 2025 | 1.3082 | -0.0100 | -0.76% | 1.3182 | 1.3682 | 1.3082 |
| Mar 24, 2025 | 1.3582 | 0.0100 | 0.74% | 1.3482 | 1.4182 | 1.3382 |
| Mar 21, 2025 | 1.3382 | 0.0200 | 1.52% | 1.3182 | 1.3582 | 1.3082 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cortexyme Inc. Company profile
About Cortexyme Inc
Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
601 Gateway Boulevard, Suite 1250
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com